- cafead Nov 10, 2020 at 11:12: AM
via About a month ago, upon touting new oncology data, Merck reaffirmed its commitment to exploring new Keytruda combinations for lung cancer patients. The Big Pharma has now pulled the plug on one of those combinations, after interim data showed an increased risk and no reward.
article source
article source